# Combination Therapy for Recurrent Ovarian Cancer

> **NCT05610735** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sham Sunder Kakar** · enrollment: 72 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** DOXIL
- **DRUG:** Withaferin A
- **DRUG:** Ashwagandha
- **DRUG:** Combination of ASWD and DOXIL

## Key facts

- **NCT ID:** NCT05610735
- **Lead sponsor:** Sham Sunder Kakar
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610735, "Combination Therapy for Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT05610735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*